The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.
AMM advisors will engage with governments, policymakers, regulators and other stakeholders in North America, Europe and Asia Pacific to advocate for policies that encourage innovation, define regulatory standards, support manufacturing and promote access of mRNA medicines to patients.
AMM members represent some of the most recognized mRNA innovators in the field. Bringing the best minds together, we aim to overcome the most critical obstacles inhibiting the advancement of mRNA research, development and manufacturing. Furthermore, AMM will forge inclusive and collaborative partnerships with other networking forums to co-publish, augment or improve upon technical and scientific content generated by these groups.
The rapid evolution of mRNA medicines since the inception of the COVID vaccine has created a need to (1) elevate the understanding and perception of mRNA medicines to the general public and (2) develop and expand the pool of mRNA talent in the industry. AMM will champion causes and projects to educate the community on the potential of mRNA technologies to improve the human condition and collaborate with institutions to uplevel and standardize the education of mRNA scientists and to retain them in the field.
AMM will serve as the leading convenor of mRNA stakeholders, bringing together innovators in the field to propel the future of mRNA medicine and advance scientific knowledge.
Board Chair
Replicate Bioscience
Board Vice-Chair
Arcturus Therapeutics
Board Treasurer
Project Farma and Precision ADVANCE
Board Secretary
Maravai Life Sciences
At-Large Board Executive
Danaher
At-Large Board Executive
BioNTech
Patrick Thiaville
4BaseBio
Pooja Tiwari
AAARNA Therapeutics Pvt Ltd and ARNAV Biotech
Chris Murphy
Akron Biotech
Ying Tam
Akron Biotech
Deborah Barbara
AMM Foundation Chair
Marco Pupo
Anemocyte
Ye Zhang
Arcturus Therapeutics
Melanie Cerullo
Arranta Bio
Archa Fox
Australian Centre for RNA Therapeutics in Cancer
Thomas Preiss
Australian National University
Timothy Mercer
BASE
Andreas Kuhn
BioNTech
Harris Makatsoris
Centillion Technology Ltd
Nelson Goncalves Fernandes
Certest Pharma
Dave Schmickel
CSL
Vicent Nebot
Curapath
Thaminda Ramanayake
CureVac
Daria Donati
Cytiva
Remo Moomiaie-Qajar
Cytonus
Mayealie Adams
Danaher
Mayealie Adams
Danaher
Yong Jae Kim
De novo
Peter Chu
Eclipse BioInnovations
Bernard Sagaert
etherna
Thomas Langenickel
Ethris
Andrew Klauk
Exothera
Dominika Nowis
ExploRNA Therapeutics
Tracy Meffen
Genevant Sciences
Joel Harris
Genvax
Narendra Maheshri
Ginkgo Bioworks
Loren Beck
HDT Bio Corp.
David Butler
Hongene Biotech Corporation
Prakash Koodathingal
Immunomic Therapeutic Inc.
Zoser Salama
IPSS
Jeff Coller
Johns Hopkins
Kate Broderick
Maravai LifeSciences
Jack Horgan
MaxCyte
Gloria Olivier
Mayo Clinic
Brett Logan
Merck
Richard Sayre
Mercury Bio
Andrew McIntosh
Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training
Lily Pisani
Nature’s Toolbox, Inc.
Ryan Swoboda
Navan Bio
Breton Hornblower
New England Biolabs
Gisela Mautner
Noxopharm
Han Teng Wong
Nucleic Acids Therapeutics Initiative
Ian Wiener
Nutcracker
David Weinberg
Parcel Biosciences, Inc.
Michele Rubino
Primrose Bio
Anshul Mangal
Project Farma
Guillaume Roelandts
Quantoom
Sophia Lugo
Radar Therapeutics
Melanie Cerullo
ReciBioPharm
Erica Jefferson
ReCode Therapeutics
Andrew Geall
Replicate Bioscience
Andrew Varley
RNA & Formulation Core at University Of British Columbia
James Nolan
Sail Biomedicines
Miroslav Gasparek
Sensible Biotechnologies, Inc.
Patty Limphong
SoCal Biosciences
Jose Vicente Pons
Syngoi Technologies SLU
Dominik Lipka
SyVento Biotech
Baley Reeves
Texas A&M National Center for Therapeutics Manufacturing
Enrico Steiner
ThermoFisher Scientific
Christian Cobaugh
Vernal
Fred Fiedorek
Verve
Sia Anagnostou
Whywevax
Khaled Yamout
Yamout Chem Consulting, LLC
Leonie Wyffels
Ziphius Vaccines
Executive Director
Managing Director
Senior Advisor
AMM members represent some of the most recognized mRNA innovators in the field. Bringing the best minds together, we aim to overcome the most critical obstacles inhibiting the advancement of mRNA research, development and manufacturing.
Interested in becoming a member of AMM? Check out the benefits of membership below.
Leverage the combined strength of the global mRNA community to define and advance the sector’s top policy priorities before influential legislative leaders in North America, Europe, and Asia.
Accelerate your projects through our proactive engagement with regulatory agencies, working towards the swift approval of new mRNA therapeutics and vaccines. Spearhead global efforts to establish quality manufacturing standards and metrics.
In the rapidly advancing world of mRNA and RNA medicines, AMM members gain exclusive insights into the cutting-edge technology and research driving our sector forward. AMM promotes technological collaborations between our members and leading tech innovators worldwide, and invites members to take part in AMM’s Science and Technology work groups.
Our comprehensive awareness and education program increases understanding of mRNA and next-generation encoding RNA therapeutics and vaccines’ potential. Our global communications strategy educates the marketplace and policy arenas, and offers members timely, relevant, and impactful industry news.
Connect with our community of innovators, therapeutic developers, and key opinion leaders at AMM’s exclusive networking events. From our annual flagship meeting to smaller regional roundtables, you’ll engage with experts and leaders shaping the industry.
Gain unparalleled access to our growing industry data resources — a robust collection of third-party sources and our own proprietary research. Access global mRNA and next-generation RNA research, investments, and insights. From clinical to financial data, we will ensure you have the knowledge to track sector progress through our regular reports.
Through our partnerships with industry stakeholders, we’re committed to nurturing talent with resources dedicated to training and development. Equip your team with the skills needed to drive your organization forward.
AMM partners with investor groups and financial institutions — critical connections that can support your organization’s capacity to secure capital for R&D — and invites members to join focused investor events, attracting investment for your initiatives.
